TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30670069

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (78.2%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antihypertensive drugs (72.3%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (72.3%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Revascularization (57.4%)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: BMI (HR=0.49, 95% CI 0.30-0.81, p=0.005)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Stroke (HR=7.37, 95% CI 2.35-23.1, p=0.001)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Revascularization (HR=0.51, 95% CI 0.27-0.94, p=0.032)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Age at admission (HR=0.81, 95% CI 0.69-0.94, p=0.006)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Renal artery involvement (HR=0.49, 95% CI 0.25-0.96, p=0.037)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Elevated C-reactive protein (HR=2.50, 95% CI 1.24-5.00, p=0.01)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: BMI level (p=0.024)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Renal artery involvement (p=0.015)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Revascularization (p=0.002)
Number of subjects: 101
Study: 30670372

Group type: EXPERIMENTAL
Intervention: Pivot program (comprehensive digital smoking cessation program)
Number of subjects: 319
Study: 30670498

Group type: EXPERIMENTAL
Intervention: YH25448
Number of subjects: 0

Group type: COMPARATOR
Intervention: osimertinib
Number of subjects: 0
Study: 30670667

Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound indices (diaphragmatic thickening fraction, diaphragmatic excursion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Time to first liberation attempt
Number of subjects: 30
Study: 30671005

Group type: EXPERIMENTAL
Intervention: Brief psychological treatment based on Unified Protocol (UP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional psychological treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional psychological treatment plus pharmacological treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Minimum intervention based on basic psychoeducational information
Number of subjects: 165

Group type: COMPARATOR
Intervention: Pharmacological treatment only
Number of subjects: 165
Study: 30671262

Group type: EXPERIMENTAL
Intervention: Vertical split conjunctival autograft using fibrin glue
Number of subjects: 15
Study: 30671283

Group type: EXPERIMENTAL
Intervention: Mindfulness for Interdisciplinary HCPs (MIHP) - an 8-week, group-based course with weekly meditation training, gentle yoga, and discussions.
Number of subjects: 18
Study: 30662958

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed rewards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no rewards)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual rewards for diabetes management, details on dosage and duration not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed rewards for diabetes management, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details on intervention not available
Number of subjects: 0
Study: 30672136

Group type: EXPERIMENTAL
Intervention: Oral sirolimus
Number of subjects: 18
Study: 30672141

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPI plus histamine-2 (H2) blocker
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (H2 blocker alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest X-ray (CXR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospitalization for respiratory indications
Number of subjects: 0
Study: 30672309

Group type: EXPERIMENTAL
Intervention: Zn/PSA ratio
Number of subjects: 480

Group type: COMPARATOR
Intervention: PSA
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Zn/PSA
Number of subjects: 480
Study: 30672741

Group type: EXPERIMENTAL
Intervention: SOVA websites and enhanced usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care alone
Number of subjects: 0
Study: 30673992

Group type: EXPERIMENTAL
Intervention: Avaxim (Hepatitis A Virus Vaccine)
Number of subjects: 614
Study: 30674285

Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative binomial and beta-binomial models
Number of subjects: 0
Study: 30674442

Group type: EXPERIMENTAL
Intervention: System A (deep learning algorithm for visual features)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: System B (sonification-derived diagnostic layer)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Heuristic analysis of Systems A and B
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: OBS analysis of raw sound dermoscopies
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: OBS image analysis of spectrograms
Number of subjects: 63
Study: 30674451

Group type: EXPERIMENTAL
Intervention: Three week cast immobilisation (n=83)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Three week orthosis (n=80)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Six week cast immobilisation (n=84)
Number of subjects: 247
Study: 30674731

Group type: EXPERIMENTAL
Intervention: 2 mg/d oral nitisinone
Number of subjects: 5
Study: 30674905

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy (liposomal doxorubicin or temozolomide)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) with systemically administered chemotherapy
Number of subjects: 5
Study: 30675234

Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, followed by maintenance therapy for non-progressors
Number of subjects: 283

Group type: COMPARATOR
Intervention: Bevacizumab (7.5 mg/kg, q3w) with platinum-doublet chemotherapy for up to 6 cycles, without maintenance therapy
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Overall cohort (all patients)
Number of subjects: 283
Study: 30675375

Group type: EXPERIMENTAL
Intervention: Service user-held Physical health plan (PHP) used for 6 months in two community mental health teams.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus groups and interviews with service users and clinical staff.
Number of subjects: 0
Study: 30675373

Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviewing
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study: 30675961

Group type: EXPERIMENTAL
Intervention: EM-guided percutaneous lung biopsy
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: EM-guided percutaneous lung biopsy with bronchoscopic sampling
Number of subjects: 129
Study: 30676359

Group type: EXPERIMENTAL
Intervention: Adults living with HIV
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: African Americans with HIV
Number of subjects: 51
Study: 30677263

Group type: EXPERIMENTAL
Intervention: 1-month responders (≥ 3% BMI reduction)
Number of subjects: 687

Group type: COMPARATOR
Intervention: Nonresponders (< 3% BMI reduction)
Number of subjects: 687
Study: 30677460

Group type: EXPERIMENTAL
Intervention: Liver transplantation (OLT)
Number of subjects: 80
Study: 30678470

Group type: EXPERIMENTAL
Intervention: Insulin balanced infusion system (IBIS)
Number of subjects: 15
Study: 30678703

Group type: EXPERIMENTAL
Intervention: Existing digital ulcer (DU) classification
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: New categorisation of DU (episodic, recurrent, chronic)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Essential items for DU evaluation
Number of subjects: 148
Study: 30678713

Group type: EXPERIMENTAL
Intervention: SERI osteotomy
Number of subjects: 29
Study: 30678753

Group type: EXPERIMENTAL
Intervention: Single-molecule counting high-sensitivity troponin I (hsTnI) with normal range <6 ng/l
Number of subjects: 4021
Study: 30679026

Group type: EXPERIMENTAL
Intervention: FOLFOX-based regimens (folinic acid, fluorouracil, and oxaliplatin)
Number of subjects: 3223
Study: 30679147

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 32
Study: 30679151

Group type: EXPERIMENTAL
Intervention: Access to Resources in the Community (ARC) navigation model
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Navigation services
Number of subjects: 82
Study: 30679214

Group type: EXPERIMENTAL
Intervention: Consecutive, multidose use of iodinated contrast during CTA and DSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30679288

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) at doses of 30, 40, 50, or 60 mg/kg as a loading dose followed by maintenance doses of a quarter of the loading dose every 8 hours.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 50
Study: 30679333

Group type: EXPERIMENTAL
Intervention: Simplified adductor canal (SAC) block
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SAC block
Number of subjects: 40
Study: 30679332

Group type: EXPERIMENTAL
Intervention: Perineural dexmedetomidine (1 mL dexmedetomidine 100 µg/mL + 4 mL ropivacaine 5 mg/mL)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Systemic dexmedetomidine (1 mL saline + 4 mL ropivacaine 5 mg/mL)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (NoDex: 1 mL saline + 4 mL ropivacaine 7.5 mg/mL)
Number of subjects: 22
Study: 30679337

Group type: EXPERIMENTAL
Intervention: Obturator Nerve Block (ONB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 60
Study: 30679389

Group type: EXPERIMENTAL
Intervention: LB-100 (experimental cancer therapeutic)
Number of subjects: 0
Study: 30680179

Group type: EXPERIMENTAL
Intervention: Whole grain consumption
Number of subjects: 530176

Group type: EXPERIMENTAL
Intervention: Refined grain consumption
Number of subjects: 530176

Group type: COMPARATOR
Intervention: Cereal exposure
Number of subjects: 530176
Study: 30680225

Group type: EXPERIMENTAL
Intervention: DACC-coated dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-coated occlusive absorbent post-operative dressing
Number of subjects: 0
Study: 30680237

Group type: EXPERIMENTAL
Intervention: Afalaza
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30680407

Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg and Grazoprevir 100 mg once daily for 10 days
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (EBR/GZR)
Number of subjects: 24
Study: 30680449

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing chemotherapy
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Panitumumab-containing chemotherapy
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Higher ECOG score
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 2533
Study: 30680635

Group type: EXPERIMENTAL
Intervention: Unsupervised 5-repetition sit-to-stand test (5R-STS)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Telesupervised 5-repetition sit-to-stand test (5R-STS)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Unsupervised at-home assessment using the 5R-STS
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Telesupervised recording assessment
Number of subjects: 121
Study: 30680661

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 12
Study: 30680676

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 0
Study: 30680712

Group type: EXPERIMENTAL
Intervention: PF-06647263 administered every week (QW)
Number of subjects: 48

Group type: COMPARATOR
Intervention: PF-06647263 administered every 3 weeks (Q3W)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PF-06647263 at the recommended phase 2 dose (RP2D) of 0.015 mg/kg QW
Number of subjects: 48
Study: 30681243

Group type: EXPERIMENTAL
Intervention: Real-time exhaled breath analysis using secondary electrospray ionization-mass spectrometry
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (matched subjects without IPF)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Real-time exhaled breath analysis
Number of subjects: 21
Study: 30681262

Group type: EXPERIMENTAL
Intervention: Severe calcification
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Moderate calcification
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: None/mild calcification
Number of subjects: 350
Study: 30681551

Group type: EXPERIMENTAL
Intervention: CytoSorb treatment (2 consecutive 24-hour treatments)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (60 matched controls with advanced hemodynamic monitoring)
Number of subjects: 30
Study: 30681643

Group type: EXPERIMENTAL
Intervention: C3 rs2230199 GG genotype in ARI2 group (55.9%)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: ARMS2 (rs10490924) T allele and CFH (rs1061170) C allele
Number of subjects: 68
Study: 30681793

Group type: EXPERIMENTAL
Intervention: ATX-101 (deoxycholic acid injection)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Energy-based devices
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Surgical liposuction
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Laser liposuction
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Other treatments
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1029
Study: 30681798

Group type: EXPERIMENTAL
Intervention: High-intensity precision RF and fractional laser therapy
Number of subjects: 19
Study: 30681965

Group type: EXPERIMENTAL
Intervention: MI-BP app for hypertension self-management
Number of subjects: 396

Group type: COMPARATOR
Intervention: Usual care methods
Number of subjects: 396
Study: 30681964

Group type: EXPERIMENTAL
Intervention: LYNX mobile app
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study: 30682081

Group type: EXPERIMENTAL
Intervention: Profile likelihood based pointwise confidence intervals (CIs) for a nonlinear dose-response model.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Profile likelihood based pointwise confidence intervals (CIs) for nonlinear dose-response models.
Number of subjects: 0
Study: 30682530

Group type: EXPERIMENTAL
Intervention: ADHD symptom severity
Number of subjects: 80
Study: 30682562

Group type: EXPERIMENTAL
Intervention: Melody valve implant
Number of subjects: 136
Study: 30683193

Group type: EXPERIMENTAL
Intervention: Endovascular TAAA repair using a stent graft
Number of subjects: 142
Study: 30683424

Group type: EXPERIMENTAL
Intervention: DREAMS 2G implantation
Number of subjects: 24
Study: 30683464

Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous time Bayesian networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic Bayesian networks (ignoring time)
Number of subjects: 0
Study: 30683996

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Previous immunisation with 23-valent polysaccharide pneumococcal vaccine (PPSV23)
Number of subjects: 34
Study: 30684076

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily for 24 weeks
Number of subjects: 9
Study: 30684309

Group type: EXPERIMENTAL
Intervention: Glibenclamide oral suspension
Number of subjects: 10
Study: 30684428

Group type: EXPERIMENTAL
Intervention: Mobile phone use
Number of subjects: 2
Study: 30684432

Group type: EXPERIMENTAL
Intervention: Facebook smoking cessation intervention with monetary incentive (up to US $90 for posting)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Facebook smoking cessation intervention without monetary incentive
Number of subjects: 138

Group type: COMPARATOR
Intervention: Not Ready group (incentive)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Not Ready group (no incentive)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Thinking and Getting Ready groups
Number of subjects: 138
Study: 30684438

Group type: EXPERIMENTAL
Intervention: Stress management app (StressProffen) developed based on cognitive behavioral strategies, usability tested with cancer survivors (n=6), healthy volunteers (n=7), healthcare providers (n=2), and eHealth experts (n=5).
Number of subjects: 48
Study: 30684505

Group type: EXPERIMENTAL
Intervention: Education-based intensified insulin therapy (EBIIT)
Number of subjects: 151
Study: 30685284

Group type: EXPERIMENTAL
Intervention: Counseling intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: No negative LARC stories
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Negative LARC stories
Number of subjects: 60
Study: 30685334

Group type: EXPERIMENTAL
Intervention: Frequent exacerbators
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nonfrequent exacerbators
Number of subjects: 52
Study: 30685564

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 67
Study: 30685579

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: SIRS score
Number of subjects: 409
Study: 30685808

Group type: EXPERIMENTAL
Intervention: G-CSF-primed haplo-identical HSCT (Haplo-ID)
Number of subjects: 131

Group type: COMPARATOR
Intervention: HLA-identical HSCT (HLA-ID)
Number of subjects: 131
Study: 30686306

Group type: EXPERIMENTAL
Intervention: Increased portal flow pulsatility fraction (≥50%)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Systolic right ventricular dysfunction
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Diastolic right ventricular dysfunction
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Portal flow assessment
Number of subjects: 115
Study: 30686303

Group type: EXPERIMENTAL
Intervention: Preoperative NLR >4
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte count (lower)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Preoperative monocyte count (higher)
Number of subjects: 1652

Group type: EXPERIMENTAL
Intervention: Monocyte ROS generation
Number of subjects: 1652
Study: 30686308

Group type: EXPERIMENTAL
Intervention: Postoperative care in paediatric surgical patients
Number of subjects: 2024
Study: 30686577

Group type: EXPERIMENTAL
Intervention: Inappropriate/unwanted comments or behavior by male veterans
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Experiences of harassment
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Feeling welcome at VA
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Feeling safe at VA
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Delaying/missing care
Number of subjects: 1395
Study: 30686583

Group type: EXPERIMENTAL
Intervention: 20 mg of oral cortisol (CORT)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 30686586

Group type: EXPERIMENTAL
Intervention: mAb114 5 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: mAb114 25 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: mAb114 50 mg/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: mAb114 (all doses)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: mAb114
Number of subjects: 19
Study: 30686676

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of PLX-PAD cells
Number of subjects: 246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study: 30686756

Group type: EXPERIMENTAL
Intervention: Metformin added to abiraterone at 1000 mg twice daily in uninterrupted 4-week cycles
Number of subjects: 25
Study: 30686767

Group type: EXPERIMENTAL
Intervention: Lumacaftor 100 mg and ivacaftor 125 mg (bodyweight <14 kg) or lumacaftor 150 mg and ivacaftor 188 mg (bodyweight ≥14 kg) orally every 12 h for 15 days (part A) and for 24 weeks (part B)
Number of subjects: 72
Study: 30686953

Group type: EXPERIMENTAL
Intervention: Binocular stimulus
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Monocular stimulus
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pinhole glasses
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monocular stimulus (dominant eye, non-dominant eye, ipsilateral, contralateral)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stronger refractive stimuli
Number of subjects: 32
Study: 30687117

Group type: EXPERIMENTAL
Intervention: Polyphenol Rich Curry
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no curry or lower doses)
Number of subjects: 0
Study: 30687164

Group type: EXPERIMENTAL
Intervention: Physical Education Program (PEP), 2 hours per week for 16 weeks
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 119
Study: 30687208

Group type: EXPERIMENTAL
Intervention: Games for Older Adults Active Life (GOAL) Project intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 30687504

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic partial pleurectomy/decortication (VAT-PD)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 38
Study: 30687508

Group type: EXPERIMENTAL
Intervention: Invasive coronary artery function-guided diagnosis and treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multiparametric CMR assessment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Multiparametric CMR
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no invasive coronary artery function-guided diagnosis and treatment)
Number of subjects: 150
Study: 30687584

Group type: EXPERIMENTAL
Intervention: Ambulation orderly (AO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study: 30687714

Group type: EXPERIMENTAL
Intervention: Curcumin Phytosome (CP) 2 g/day for 2 weeks
Number of subjects: 7
Study: 30687792

Group type: EXPERIMENTAL
Intervention: MVA85A vaccine, details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0